HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Free Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (69) Citing Articles via Google Scholar Google Scholar Articles by Harari, P M Search for Related Content PubMed PubMed Citation Articles by Harari, P M

University of Wisconsin Medical School, Department of Human Oncology, University of Wisconsin Medical School, 600 Highland Avenue K4/332, Madison, Wisconsin 53792, USA

(Requests for offprints should be addressed to P M Harari; Email: harari{at}humonc.wisc.edu)

Molecular targeting strategies for cancer therapy are distinct from conventional chemotherapy and radiotherapy in their potential to provide increased tumor specificity. One particular molecular target of high promise in oncology is the epidermal growth factor receptor (EGFR). The EGFR is overexpressed, dysregulated or mutated in many epithelial malignancies, and EGFR activation appears important in tumor growth and progression. Advances in signal transduction biology continue to sharpen our understanding regarding specific contributions of EGFR signaling networks to cancer behavior. Two predominant classes of EGFR inhibitors have been developed including monoclonal antibodies (mAbs) that target the extracellular domain of EGFR, such as cetuximab (Erbitux), and small molecule tyrosine kinase inhibitors (TKIs) that target the receptor catalytic domain of EGFR, such as gefitinib (Iressa) and erlotinib (Tarceva).

Mechanisms of action for EGFR inhibitors have been investigated in preclinical model systems. Safety, activity, pharmacokinetics and pharmacodynamics have been assessed in clinical trials. The anti-EGFR mAbs and TKIs have partially overlapping toxicity profiles, but distinct routes of administration, serum half-lives and therefore dosing schedules. Both classes of agents show clear antitumor activity, and cetuximab and gefitinib have been recently FDA approved for colorectal and lung cancer indications respectively. However, the absence of survival benefit for EGFR TKIs in combination with chemotherapy in large-scale phase III lung cancer trials in 2003 underscores a major challenge in anti-EGFR oncology therapeutics; namely to identify those tumors and patients that will respond predictably to EGFR inhibitor approaches. Newly identified mutations in the EGFR catalytic domain that appear to confer sensitivity to EGFR TKIs promise to open new doors of investigation regarding response prediction. Advances will also require enhanced molecular understanding of the overall EGFR signaling network, and improved methods to gauge the dependence of individual tumors on EGFR signaling pathways for growth advantage. Results from newly reported phase III trials in 2004 now confirm a survival advantage for the use of EGFR inhibitors in combination with high-dose radiation in head and neck cancer, and in refractory lung cancer respectively. It appears likely that EGFR inhibitors (and other rationally designed molecular growth inhibitors) will play a meaningful role in cancer therapy in the years to come.

This article has been cited by other articles:

				K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF]

				F. Y. Feng, C. A. Lopez, D. P. Normolle, S. Varambally, X. Li, P. Y. Chun, M. A. Davis, T. S. Lawrence, and M. K. Nyati Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo Clin. Cancer Res., April 15, 2007; 13(8): 2512 - 2518. [Abstract] [Full Text] [PDF]

				B. Brandt, S. Meyer-Staeckling, H. Schmidt, K. Agelopoulos, and H. Buerger Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response Clin. Cancer Res., December 15, 2006; 12(24): 7252 - 7260. [Abstract] [Full Text] [PDF]

				S. Urban Rhomboid proteins: conserved membrane proteases with divergent biological functions. Genes & Dev., November 15, 2006; 20(22): 3054 - 3068. [Abstract] [Full Text] [PDF]

				H.-J. Lenz, E. Van Cutsem, S. Khambata-Ford, R. J. Mayer, P. Gold, P. Stella, B. Mirtsching, A. L. Cohn, A. W. Pippas, N. Azarnia, et al. Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines J. Clin. Oncol., October 20, 2006; 24(30): 4914 - 4921. [Abstract] [Full Text] [PDF]

				E. Van Cutsem Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer Oncologist, October 1, 2006; 11(9): 1010 - 1017. [Abstract] [Full Text] [PDF]

				P. Schoffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P. Wolter, S. Joniau, T. Roskams, and H. Van Poppel Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review Ann. Onc., August 1, 2006; 17(8): 1185 - 1196. [Abstract] [Full Text] [PDF]

				F. T. Lee, A. J. Mountain, M. P. Kelly, C. Hall, A. Rigopoulos, T. G. Johns, F. E. Smyth, M. W. Brechbiel, E. C. Nice, A. W. Burgess, et al. Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478 Clin. Cancer Res., October 1, 2005; 11(19): 7080s - 7086s. [Abstract] [Full Text] [PDF]

				W. A. Woodward, M. S. Chen, F. Behbod, and J. M. Rosen On mammary stem cells J. Cell Sci., August 15, 2005; 118(16): 3585 - 3594. [Abstract] [Full Text] [PDF]

				R Duncan, M J Vicent, F Greco, and R I Nicholson Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S189 - S199. [Abstract] [Full Text] [PDF]

				P. M. Harari Promising new advances in head and neck radiotherapy Ann. Onc., January 1, 2005; 16(suppl_6): vi13 - vi19. [Abstract] [Full Text] [PDF]